Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia

NCT ID: NCT01909336

Last Updated: 2016-12-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

161 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if isotonic solutions reduce the risk of hospital acquired hyponatremia compared with hypotonic solutions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multicenter, Randomized, Controlled clinical trial.

The purpose of this study is to determine if isotonic solutions reduce the risk of hospital acquired hyponatremia compared with hypotonic solutions

This study will include 150 patients in 2 groups according to these type of pathology: group 1: medical conditions which includes respiratory problems (pneumonia, bronchiolitis, acute asthma attack) and acute gastrointestinal problems (bacterial or viral gastroenteritis) and group 2: surgical conditions (pre, peri or postoperative patients will be included). Each group will be randomized to receive 3 types of interventions: 0.3% Saline (hypotonic solution), 0.45% Saline (hypotonic solution) or 0.9% Saline (isotonic solution). In non-dehydrated patients the daily total volume of liquid infused will be determined by the volumetric Holliday- Segar\* formula and the daily total volume will be calculated by adding the maintenance requirements (using the Holliday Segar formula) to the fluid deficit (according to percent of estimated weight\*\*) in dehydrated patients.

The glucose concentrations in the first group will be 3.3%, and in group 2 and 3 will be 5%. The potassium concentration will be 20mEq/L in all groups. Blood samples will be collected before, 8 hours and 24 hours after the start of intravenous fluid, for the analysis of sodium, potassium, glucose, urea and creatinine. The adverse clinical outcomes at 8 and 24 hours of the start of intravenous fluid will also be recorded. The sodium plasma level, the incidence of hyponatremia and the adverse clinical outcomes will be compared.

\*0-10 kilogram (kg): 100ml/kg per day; 10-20 kg: 1000 ml + 50 ml/kg/day over 10 kg; \>20 kg: 1500 ml + 20ml/ kg over 20kg

\*\* In patients under 10 kg correspond to a loss of 5% (50 mL/kg) in mild dehydration and 10% in moderate dehydration. In 10 kg or more: 3% (30 mL/kg) in mild dehydration and 6% (60 mL/kg) in moderate dehydration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyponatremia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: 0.3% Saline in 3.3% dextrose (intravenous)

Group 1: 0.3% Saline in 3.3% dextrose (intravenous)

Group Type ACTIVE_COMPARATOR

0.3% Saline in 3.3% dextrose

Intervention Type DRUG

Hypotonic Solutions: 0.3% Saline in 3.3% dextrose

Group 2: 0.45% Saline in 5% dextrose (intravenous)

Group 2: 0.45% Saline in 5% dextrose (intravenous)

Group Type ACTIVE_COMPARATOR

0.45% Saline in 5% dextrose

Intervention Type DRUG

Hypotonic Solutions: 0.45% Saline in 5% dextrose

Group 3: 0.9% Saline in 5% dextrose (intravenous)

Group 3: 0.9% Saline in 5% dextrose (intravenous)

Group Type ACTIVE_COMPARATOR

0.9% Saline in 5% dextrose

Intervention Type DRUG

Isotonic Solutions 0.9% Saline in 5% dextrose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.3% Saline in 3.3% dextrose

Hypotonic Solutions: 0.3% Saline in 3.3% dextrose

Intervention Type DRUG

0.45% Saline in 5% dextrose

Hypotonic Solutions: 0.45% Saline in 5% dextrose

Intervention Type DRUG

0.9% Saline in 5% dextrose

Isotonic Solutions 0.9% Saline in 5% dextrose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hypotonic Solutions: 0.3% Saline + 3.3% dextrose Hypotonic Solutions: 0.45% Saline in 5% dextrose Isotonic Solutions 0.9% Saline in 5% dextrose

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children between 3 months to 15 years.
* Need for intravenous fluids for 8 hours or more.
* Normal serum sodium at the beginning of the study of the study (135-145 mEQ/L).
* Acute respiratory problems (acute asthma attack, bronchiolitis or pneumonia).
* Acute gastrointestinal disorders (viral o bacterial gastroenteritis).
* Elective surgical procedures.
* Pre, peri o post operative patients (acute appendicitis, intussusception, intestinal perforation, ileus).

Exclusion Criteria

* Severe hyponatremia (serum sodium \< 125 mEq/L).
* Severe hypernatremia (serum sodium \>155 mEq/L).
* Need for intravenous fluids for less than 8 hours according with their treating physician.
* Severe dehydration or Shock.
* Preexisting chronic diseases (renal diseases, heart diseases or endocrine disorders).
* Neurologic diseases.
* Head trauma.
* Cerebral edema or Intracranial hypertension.
* Diabetic ketoacidosis.
* Use of diuretics one week or less before the study.
* Need for admission to the pediatric critical intensive care unit
Minimum Eligible Age

3 Months

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tecnologico de Monterrey

OTHER

Sponsor Role collaborator

Instituto Tecnologico y de Estudios Superiores de Monterey

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Claudia Montserrat Flores Robles, MD

Claudia Montserrat Flores Robles

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Claudia Montserrat Flores Robles, MD

Role: PRINCIPAL_INVESTIGATOR

Tecnologico de Monterrey

Carlos Alberto Cuello García, MD

Role: STUDY_DIRECTOR

Centro de Medicina Basada en Evidencias, Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey.

References

Explore related publications, articles, or registry entries linked to this study.

Moritz ML, Ayus JC. Hospital-acquired hyponatremia--why are hypotonic parenteral fluids still being used? Nat Clin Pract Nephrol. 2007 Jul;3(7):374-82. doi: 10.1038/ncpneph0526.

Reference Type BACKGROUND
PMID: 17592470 (View on PubMed)

Choong K, Kho ME, Menon K, Bohn D. Hypotonic versus isotonic saline in hospitalised children: a systematic review. Arch Dis Child. 2006 Oct;91(10):828-35. doi: 10.1136/adc.2005.088690. Epub 2006 Jun 5.

Reference Type BACKGROUND
PMID: 16754657 (View on PubMed)

Montanana PA, Modesto i Alapont V, Ocon AP, Lopez PO, Lopez Prats JL, Toledo Parreno JD. The use of isotonic fluid as maintenance therapy prevents iatrogenic hyponatremia in pediatrics: a randomized, controlled open study. Pediatr Crit Care Med. 2008 Nov;9(6):589-97. doi: 10.1097/PCC.0b013e31818d3192.

Reference Type BACKGROUND
PMID: 18838929 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SIvsSHnh

Identifier Type: -

Identifier Source: org_study_id